Details

Autor(en) / Beteiligte

• Namiki, Sanae
• Kawase, Makoto
• Ebara, Shin
• Tatenuma, Tomoyuki
• Sasaki, Takeshi
• Ikehata, Yoshinori
• Nakayama, Akinori
• Toide, Masahiro
• Yoneda, Tatsuaki
• Sakaguchi, Kazushige
• Teishima, Jun
• Makiyama, Kazuhide
• Inoue, Takahiro
• Kitamura, Hiroshi
• Saito, Kazutaka
• Koga, Fumitaka
• Urakami, Shinji
• Koie, Takuya

Titel

Pelvic Lymphadenectomy May Not Improve Biochemical Recurrence-Free Survival in Patients with Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy in Japan (The MSUG94 Group)

Ist Teil von

• Cancers, 2022-11, Vol.14 (23), p.5803

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2022

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• In this multicenter retrospective cohort study, we aimed to evaluate whether pelvic lymph node dissection (PLND) improved biochemical recurrence (BCR) in patients with prostate cancer (PCa) who underwent robot-assisted radical prostatectomy (RARP) in Japan. A multicenter retrospective cohort study of 3195 PCa patients undergoing RARP at nine institutions in Japan was conducted. Enrolled patients were divided into two groups: those who underwent RARP without PLND (non-PLND group) and those who underwent PLND (PLND group). The primary endpoint was biochemical recurrence-free survival (BRFS) in PCa patients who underwent PLND. We developed a propensity score analysis to reduce the effects of selection bias and potential confounding factors. Propensity score matching resulted in 1210 patients being enrolled in the study. The 2-year BRFS rate was 95.0% for all patients, 95.8% for the non-PLND group, and 94.3% for the PLND group ( = 0.855). For the all-risk group according to the National Comprehensive Cancer Network risk stratification, there were no significant differences between patients who did and did not undergo PLND. Based on the results of the log-rank study, PLND may be unnecessary for patients with PCa undergoing RARP.